Redmile Group LLC acquired a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,219,616 shares of the biopharmaceutical company’s stock, valued at approximately $66,344,000. Juno Therapeutics comprises 4.0% of Redmile Group LLC’s portfolio, making the stock its 6th biggest position. Redmile Group LLC owned about 2.09% of Juno Therapeutics at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. M&T Bank Corp purchased a new position in shares of Juno Therapeutics in the 1st quarter valued at about $381,000. Laurion Capital Management LP purchased a new position in shares of Juno Therapeutics in the 1st quarter valued at about $390,000. Marshall Wace LLP purchased a new position in shares of Juno Therapeutics in the 2nd quarter valued at about $1,071,000. Geode Capital Management LLC increased its holdings in shares of Juno Therapeutics by 8.9% in the 1st quarter. Geode Capital Management LLC now owns 595,136 shares of the biopharmaceutical company’s stock valued at $13,206,000 after acquiring an additional 48,516 shares during the last quarter. Finally, Brighton Jones LLC purchased a new position in shares of Juno Therapeutics in the 2nd quarter valued at about $260,000. Institutional investors and hedge funds own 67.38% of the company’s stock.
Shares of Juno Therapeutics, Inc. (JUNO) traded down 2.48% during mid-day trading on Friday, hitting $43.61. The company had a trading volume of 1,605,085 shares. The stock’s market cap is $4.57 billion. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $47.03. The stock’s 50-day moving average is $40.64 and its 200-day moving average is $29.40.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million for the quarter, compared to analyst estimates of $15.59 million. During the same quarter in the previous year, the company earned ($0.64) EPS. The company’s quarterly revenue was down 22.8% compared to the same quarter last year. Equities analysts forecast that Juno Therapeutics, Inc. will post ($3.12) earnings per share for the current year.
A number of research analysts have recently commented on the company. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 price objective (up previously from $27.00) on shares of Juno Therapeutics in a report on Friday. Vetr upgraded Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price objective on the stock in a report on Monday, August 14th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. BidaskClub downgraded Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $44.00 price objective on shares of Juno Therapeutics in a report on Friday. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Juno Therapeutics presently has an average rating of “Hold” and an average target price of $36.45.
TRADEMARK VIOLATION NOTICE: This article was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/10/08/redmile-group-llc-invests-66-34-million-in-juno-therapeutics-inc-juno.html.
In other Juno Therapeutics news, insider Sunil Agarwal sold 7,285 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $27.00, for a total value of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold 8,085,004 shares of company stock worth $219,551,561 in the last 90 days. 15.26% of the stock is currently owned by insiders.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics, Inc. (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.